Gubra Company
Founded in 2008, they are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Their focus is the metabolic space (obesity, diabetes, NASH and diabetic complications), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. They work with some of the most interesting and loyal partners and customers from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.
Industry:
Geroscience
Headquarters:
Hørsholm, Hovedstaden, Denmark
Zip:
51-100
Founded Date:
2008-01-01
Employees Number:
51-100
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Type:
info@gubra.dk
Register and Claim Ownership